Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.66 |
| ▸ | TGFBR2 | P37173 | 8/20 | 0.66 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25204370 | 0.85 | TGFBR1 (0.56) | TGFBR1TGFBR2TLR9TLR8TLR7 | |
| SCHEMBL17840850 | 0.85 | TGFBR1 (0.74) | TGFBR1TGFBR2TLR9TLR8TLR7 | |
| SCHEMBL25227109 | 0.84 | TGFBR1 (0.74) | TGFBR1TGFBR2MAPK14PRKD1MAPK13 | |
| SCHEMBL25227829 | 0.83 | TGFBR1 (0.80) | TGFBR1TGFBR2MAPK14PRKD1MAPK13 | |
| SCHEMBL17840869 | 0.82 | TGFBR1 (0.81) | TGFBR1TGFBR2TLR9TLR8TLR7 | |
| SCHEMBL17840547 | 0.81 | TGFBR1 (0.60) | TGFBR1TGFBR2PIK3C3 | |
| SCHEMBL2892846 | 0.81 | TGFBR1 (0.80) | TGFBR1TGFBR2MAPK14PRKD1MAPK13 | |
| SCHEMBL17863740 | 0.81 | TGFBR1 (0.77) | TGFBR1TGFBR2PIK3C3MAPK14PRKD1 | |
| SCHEMBL17840602 | 0.81 | TGFBR1 (0.72) | TGFBR1TGFBR2TLR9TLR8TLR7 | |
| SCHEMBL17863739 | 0.81 | TGFBR1 (0.82) | TGFBR1TGFBR2TLR8TLR7PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4188928-B1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | BAYER AG (DE) | 2024-07-24 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| EP-4188928-A1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | TGFBR1 4404/4885TGFBR2 4317/4885TLR9 4647/4885 |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | TGFBR1 2/4885TGFBR2 1/4885TLR9 949/4885 |
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | CYP1B1, CBR1, CYP4B1 | TGFBR1 3324/4885TGFBR2 3296/4885TLR9 4770/4885 |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | CYP1B1, CYP4B1, CYP2C19 | TGFBR1 4506/4885TGFBR2 4544/4885TLR9 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.